Introduction {#S0001}
============

Bladder cancer (BC) is the second most common type of urinary tract infection worldwide. Also, it is the fourth most common cancer in men and the ninth in women,[@CIT0001] with approximately 150,000 deaths in the world.[@CIT0001]

The results of epidemiological studies show a wide range of genetic, anatomical, hormonal, social, and environmental factors in the development of disease.[@CIT0002] The incidence of this malignancy in the world is \~440,000 annually,[@CIT0003] the 5-year survival rates in the US and European countries were 76% and 68%, respectively, which is higher in high income countries than in other countries.[@CIT0004]

The statistics indicate an increasing trend in prevalence of this cancer in Iran,[@CIT0005] with more than 70,000 new cases and 30,000 annually recorded deaths.[@CIT0006] Generally, 7.04% of cancers in Iran are related to bladder cancer.[@CIT0007] The most important risk factors associated with bladder cancer include tobacco, industrial exposures, and carcinogens such as aromatic amines, black carbon, prolonged use of arsenic or chlorine contaminated water, and family history.[@CIT0008]

Information about the epidemiological situation of the disease and its risk factors is necessary for conducting a planning program to reduce the disease; also, there is no comprehensive conducted investigation in Iran that addresses various epidemiological aspects of the disease, therefore, the present study aims to examine the epidemiological aspects of bladder cancer in Iran.

Methods and Materials {#S0002}
=====================

This study systematically reviews articles carried out using national (SID, Magiran) and international databases (PubMed, Web of Science, Scopus) which were obtained from 2000--2019. The keywords included: "bladder cancer", "bladder neoplasm", "incidence", "epidemiology", "survival", "mortality", "prevalence", "risk factor", and "Iran". The search was matched for each database.

Original articles that examined epidemiological aspects of the disease, including incidence, mortality, prevalence, survival, and risk factors, were included in the study. Review articles, letters to the editor, and case reports were excluded.

Data Collection Process {#S0002-S2001}
-----------------------

Summaries and full text of the articles were independently reviewed by two authors and, if relevant for the purpose of this study, required information, including the author's name, year of publication, place of study, sex of subjects, sample size, incidence, prevalence, mortality, and risk factors were extracted from each article and recorded in relevant tables. Finally, the information was presented qualitatively in the form of the tables.

Results {#S0003}
=======

Description of Literature Search {#S0003-S2001}
--------------------------------

A total of 723 articles were reviewed, 10 articles identified through other sources, 620 articles were duplicated, 274 articles were fully studied, 239 articles were unrelated, and finally 35 articles were included in the review ([Figure 1](#F0001){ref-type="fig"}).Figure 1Flowchart of the included studies in the systematic review.

Mortality {#S0003-S2002}
---------

In Iran, the pattern of mortality rate reduction for bladder cancer is similar to that in high socioeconomic status countries. The mortality rate in the period of 1990--2015 decreased from 13.04 to 0.47 ([Table 1](#T0001){ref-type="table"}).Table 1The Mortality Rate of Bladder Cancer in IranFirst Author (Year)Province (District)Type of StudySample Size(Sex)Age-Standardized Mortality Rate per 100,000 (ASMR)Death per 100,000 PeopleBabaei (2009)[@CIT0055]Ardabil---4,363MF0.5Mazdak (2018)[@CIT0015]IsfahanRetrospective study1,655MF (2011--2012)0.562012--20130.742013--20140.982014--20150.84Pishgar (2018)[@CIT0009]ALLof iran------MF (1990)13.04 (10.04−16.95)199510.94 (8.56--13.97)20005.62 (4.46--7.08)20052.5 (3.16--1.98)20101.4 (1.78--1.1)20150.47 (0.61--0.37)Sadjadi (2005)[@CIT0077]Golestan, Mazandaran, Kerman, Ardabil Tehran2,083MF1,059Mahdavi (2015)[@CIT0078]All of Iran105MF (2006)1.1220071.0920081.1520091.120101.09

Also, increasing in smoking among men and, at the same time, reducing the amount of cigarette consumption in women can justify a reduction in the mortality rate of bladder cancer. Meanwhile, behavioral, environmental, and metabolic changes should be considered as significant factors in reducing mortality.[@CIT0009]

On the other hand, the efficacy and availability of diagnostic tools and therapeutic methods have been effective in reducing this malignancy. Nowadays, cystectomy is available for diagnosis and treatment in many parts of Iran,[@CIT0010],[@CIT0011] [Table 1](#T0001){ref-type="table"} shows the mortality of bladder cancer in Iran.

Incidence {#S0003-S2003}
---------

Bladder cancer is the fifth most common cancer in Iranian men. Based on the findings of the previous studies, the standardized incidence rate in Iran was estimated to be between 1.6--115% . The highest standardized incidence of age was observed in Eastern Azerbaijan (17.6) and Kerman province (15.8).

It should be noted that all previous findings in Iran reported that the incidence rate in men is more than that in women. This discrepancy is partly due to smoking habits differences among men and women, so that the incidence of malignancy in males is 1--4.8 in southern Iran and 1--7 in other regions of country. In addition to smoking, opium consumption and occupational exposure are important risk factors which increase the malignancy rate in men.[@CIT0006] It should be mentioned that the incidence rate in men and women varies from 1--6 to 1--2, and is higher in men than women, so that three quarters of new bladder cancer cases are observed in men,[@CIT0012] [Table 2](#T0002){ref-type="table"} shows the incidence of bladder cancer in Iran.Table 2Incidence Rate of Bladder Cancer in IranFirst Author (Year)Province (District)Type of StudySample SizeSexASR (Age-Standardized Incidence Rate)Incidence RateIncidence RatioMean±SDSomi (2008)[@CIT0048]East Azerbaijan---4,922Male\
Female15.72\
3.68Akbari (2008)[@CIT0049]Tehran---8,147Male\
Female48.3Rohani-Rasaf (2012)[@CIT0050]Tehran------MaleSep-01 (6.3)\
Sep-02 (8.2)\
Sep-03 (14.2)\
Sep-04 (15.3)Ahmadi (2018)[@CIT0051]Chahrmahal and Bakhtiari2,918MF0.08Shahesmaeili (2018)[@CIT0052]KermanRetrospective study2,838Male24.70Akbarzadeh (2012)[@CIT0053]MazandaranCross-sectional310MF11.4Aghajani (2016)[@CIT0054]All of IranRetrospective study301,055M\
F11.25\
2.49Babaei (2009)[@CIT0055]Ardabil4,363Mf13.1Basiri (2014)[@CIT0056]All of Iran------M (2003)\
M (2009)\
F (2003)\
F (2009)8.35\
12.59\
1.49\
2.44Haghdoost (2015)[@CIT0057]KermanCross-sectional3,052MF15.8Rafiemanesh (2018)[@CIT0058]North Khorasan---2,165MF5.13Rafiemanesh (2015)[@CIT0059]Sistan and Baluchistan---3,535MF (2004)1.24Zahedi (2015)[@CIT0060]Hamadan---4,592\
3,175M (2004)\
M (2009)\
F (2004)\
F (2009)72.9\
132.0\
48.2\
115.0Sadjadi (2003)[@CIT0061]Ardabil---2,072\
1,309Male\
Female7.6\
1.8Sadjadi (2007)[@CIT0062]Kerman---3,264\
2,620M\
F6.7\
1.6Somi (2018)[@CIT0063]East Azerbaijan---6,655MF17.6Salehiniya (2016)[@CIT0064]Mazandran and GolstanCross- sectional6,177\
15,231M\
F15.41\
6.77Talaiezadeh (2013)[@CIT0065]Khouzestan---16,801M\
F10.69\
4.07Fararouei (2015)[@CIT0066]Kohgiluyeh and Boyer-AhmadCohort660MF6.94Keyghobadi (2015)[@CIT0067]KermanCross-sectional5,793M (2004)\
2005\
2006\
2007\
2008\
20097.73\
9.71\
9.41\
11.17\
13.20\
14.66Mohagheghi (2009)[@CIT0068]Tehran---26,006M\
F13.3\
3.8Mazdak (2018)[@CIT0015]IsfahanRetrospective study1,655MF (2011--2012)\
2012--2013)\
2013--2014)\
2014--20157.7\
8.1\
7.5\
9.9Masoompour (2016)[@CIT0069]Fars------M (1985--1989)\
M (1998--2002)\
M (2007--2010)\
F (1985--1989)\
F (1998--2002)\
F (2007--2010)7.50\
6.8\
15.60\
2.00\
1.90\
3.93Vakili (2014)[@CIT0070]Yazd---4,631MF7.5Yavari (2008)[@CIT0071]Tehran597MF12.8±61.9Rahimi (2015)[@CIT0072]Tehran------M\
F13.3\
3.8Semnan---M\
F7.16\
3Golestan---M\
F8.7East Azerbaijan---M\
F15.72\
3.68Khuzestan---M\
F10.69\
4.07Shahroud---M\
F9.39\
3.16Rafiemanesh (2016)[@CIT0073]QOMCross-sectional3,029M (2004)\
2005\
2006\
2007\
200810.46\
7.30\
6.82\
9.49\
9.80Rafiemanesh (2018)[@CIT0074]All of IranCross-sectional23,291F (2003)\
2004\
2005\
2006\
2007\
2008\
M (2003)\
2004\
2005\
2006\
2007\
20082.12\
2.49\
2.86\
2.99\
3.32\
3.78\
8.35\
9.9\
11.3\
11.66\
13.03\
14.42Sadjadi (2005)[@CIT0062]Golestan, Mazandaran, Kerman, Ardabil Tehran---51,000M8.0Enayatrad (2016)[@CIT0075]All of Iran---41,169\
32,898M (2004)\
2005\
2006\
2007\
2009\
F (2004)\
2005\
2006\
2007\
200911.3\
11.7\
13.0\
14.4\
12.6\
2.9\
2.9\
3.3\
3.8\
3.3Koohi (2015)[@CIT0076]All of IranCross-sectional27,898MF (2003)\
2004\
2005\
2006\
2007\
2008\
20094.69\
4.70\
4.71\
4.71\
4.63\
4.48\
4.49

Survival {#S0003-S2004}
--------

The average survival rate was \~24.2 months in the country. The survival time is related to only two variables of the place of living and the type of disease, given that the economic, social, and cultural structure of the developing countries is approaching advanced countries, it can be expected that the incidence of bladder cancer in Iranian women will increase in the future, since the 5-year survival rate of bladder cancer in women is 6 years less than that of men.[@CIT0013] Also, the cumulative survival rate in Iran was 0.95%, indicating that the survival rate of BC in Iranian patients is lower than in other areas. However, the effect of early diagnosis based on updated and effective methods in advanced countries should not be underestimated. In other words, this difference can be due to the existence of a decision-making process or lead time bias.[@CIT0014] [Table 3](#T0003){ref-type="table"} shows the survival rate of bladder cancer in Iran.Table 3The Survival Rate Associated with Bladder Cancer in IranFirst Author (Year)Province (District)Type of StudySexSample SizeAverage Survival RateSurvival RateCumulative Survival RateAhmad (2003)[@CIT0013]FarsCohort HistoricalMF7624.2 (18.3--30.1)------Mohammadbeigi (2011)[@CIT0014]FarsRetrospective studyMF514---One-year survival = 0.9\
3 years = 0.7\
5 years = 0.6\
10 years = 0.20.9582Vahedian-Ardakani (2018)[@CIT0047]YazdRetrospective cohort studyMF340------One-year survival = 91\
3 years = 58\
5 years = 51.4

Prevalence {#S0003-S2005}
----------

Based on previous studies, the prevalence rate in this Iranian population was 33.2 per 100,000 people ([Table 4](#T0004){ref-type="table"}). This rate in men is 4.8-times higher than that in women.[@CIT0015] The high prevalence of this malignancy can reflect the patterns of smoking and environmental carcinogens.[@CIT0016] [Table 4](#T0004){ref-type="table"} shows the prevalence of bladder cancer in Iran.Table 4The Prevalence of Bladder Cancer in IranFirst Author (Year)Province (District)Type of StudySample SizeSexPrevalence5 Year PrevalenceNikfarjam (2014)[@CIT0079]Mashhad--4606MF4.10Farahmand (2009)[@CIT0080]Fars--1440Mf(2002)\
2003\
2004\
2005\
2006173\
201\
207\
351\
314Mazdak (2018)[@CIT0015]IsfahanRetrospective study1655MF (2011--2015)33.2Rahimi (2015)[@CIT0073]Kermanshah--7695MF12.8Roshani (2016)[@CIT0081]All of iranCross-sectional75,500MF9.6Sadjadi (2005)[@CIT0077]Golestan, Mazandaran, Kerman, Ardabil Tehran--2083MF--5970

Risk Factors {#S0003-S2006}
------------

### Smoking {#S0003-S2006-S3001}

Researchers report the high prevalence of smoking and opium consumption in the Iranian studied population.[@CIT0017] The chance of malignancy in Iran in smokers and opium users is 6.2 (2.04--18.7) and (1.8--7.8), being 8.3% times higher than those who only smoke ([Table 5](#T0005){ref-type="table"}).Table 5Risk Factors Associated with Bladder Cancer in IranFirst Author (Year)Province (District)Type of StudySample SizeSexRisk FactorsORMean (SD; Min, Max)N (%)Median 95% ClAkbari (2015)[@CIT0018]FarsCase-control198 (case)\
396 (control)Male\
FemaleOpium3.9 (1.3--12.0)Tobacco2.5 (1.3--4.8)Alcohol2.9 (1.2--7.1)Aminian (2014)[@CIT0036]TehranCase-control160 (case)\
160 (control)MaleOccupational risk:\
1-bus and truck driving3.62 (1.04--12.89)2-mechanics, working in refinery and Petrochemical, plastic2.71 (1.03--7.59)3-Textile industry, Spinning, Hosiery2.23 (0.70--7.15)4-House Keeping1.79 (0.90--3.67)5-barberry, painting, Dye Manufacturing1.81 (0.69--4.83)6-Shoe-making, production, seat cover, Embroidered bag, Repairing shoes1.12 (0.34--4.57)7-welding, metal working, plumbing, turning2.46 (0.99--6.28)8-driving1.57 (0.69--3.49)9-office job1.15 (0.65--2.0)10-carpentry, Mosaic work, cabinet making1.14 (0.27--4.07)Ahmadi (2012)[@CIT0006]MazandaranCross-sectional112MFOpium21.4Tobacco45.5History of cancer in family22.32Khoubi (2013)[@CIT0034]IsfahanCase-control300 (case)\
500 (control)Health professionals0.4 (0.04--4.80)Petroleum and natural gas refining plant operators0.4 (0.18--1.50)Clerks0.2 (0.11--2.49)Domestic housekeepers5.9 (2.61--11.62)Sales workers2.8 (0.81--2.01)Shop assistants3.4 (0.91--7.21)Skilled agricultural, forestry, and fishery workers6.0 (2.32--15.72)Animal producers2.5 (0.70--9.04)Building and related trades workers, excluding electricians3.8 (1.33--3.21)Carpenters and joiners2.9 (0.77--12.13)Painters and related workers1.8 (0.20--4.21)Sheet and structural metal workers, molders and welders6.0 (2.84--14.08)Food processing and related trades workers1.0 (0.22--3.52)Car, van, and motorcycle drivers0.6 (0.07--5.60)Heavy truck and bus drivers11.3 (1.32--92.50)Mining and construction laborers1.2 (0.30--4.41)Hosseini (2010)[@CIT0037]TehranCase-control179 (case)\
179 (control)Opium4.60 (3.53--6.28)Shakhssalim (2010)[@CIT0007]Tehran, Khorasan, Khoozestan, Isfahan and East AzarbayjanCase-control692 (case)\
692 (control)MFOpium2.57 (1.55--4.26)Hair dye1.99 (1.04--3.82)Excessive analgesics use1.41 (1.02--1.94)Sausage0.98 (0.70--1.34)Ham1.24 (0.87--1.78)Smoked fish0.78 (0.50--1.20)Can0.80 (0.60--1.07)Pickles0.93 (0.88--0.99)Fruits0.97 (0.94--1.00)Vegetables0.93 (0.89--0.97)Farzaneh (2017)[@CIT0038]YazdCase-control200 (case)\
200 (control)MFChronic or recurrent urinary5.92 (3.47--10.09)History of chronic or recurrent urinary tract infection 2--3 years8.18 (2.18--30.69)Analgesic use2.21 (1.30--3.75)History of analgesic use ≥4 years11.81 (2.83--49.18)Irradiation to pelvis1.69 (1.10--2.58)History of irradiation to pelvis ≥4-times12.68 (3.51--45.76)Kidney and bladder stones3.44 (2.06--5.75)History of kidney and bladder stones ≥2 years8.07 (2.48--26.22)History of diabetes2.15 (1.29--3.59)History of other kidney diseases2.84 (1.8--4.46)History of hypertension1.81 (1.08--3.02)History of smoking2.87 (1.47--5.59)Ghadimi (2015)[@CIT0039]KurdistanCase--control152MFEx-smoker\
Current smoker2.549 (1.287--5.048)Occupational risk:\
Driver1.714 (0.824−3.563)Loom5.134 (0.593−44.47)Carpenter3.039 (0.312--29.551)Cleaner0.688 (0.376−1.258)Painter1.342 (0.295−6.101)Metal10.629 (1.343--84.093)Construction worker0.814 (0.434--1.528)Farmer0.819 (0.513--1.308)Governmental employee1.128 (0.571−2.228)BMI\>251.041 (0.657−1.649)Lotfi (2016)[@CIT0040]YazdCase-control200 (case)\
200 (control)MFCigarette smoking3.16 (2.04--4.9)Opium History3.01(1.73--5.23)History of Hubble bubble and pipe2.63(1.48--4.64)History of alcohol2.57 (1.04--6.35)Oil Animal3.19 (1.64--6.21)Fried food (per week)4.02 (2.32--6.95)Red Meat \>45.61 (3.02--10.41)Mohseni (2004)[@CIT0041]TehranCase-control185MFSmoking in the patients with high-grade tumors15.9 (6.7--36.9)Motamed (2018)[@CIT0042]FarsRetrospective756MFHookah consumption1.44 (1.01--2.1)Hypertension1.36 (1.00--1.86)Gender1.46 (0.99--2.15)Mirsafa (2015)[@CIT0043]TehranCase-control55 (case)\
110 (control)Animal fat\
FAT19.76\
12.92Junk foods8.1Organ meat5.47Processed meat5.34Sweets3.62Jafari-Koshki (2017)[@CIT0044]All of Iran---17,792BMI\>25 (2006)43.28±6.65BMI\>25 (2007)44.59±6.18BMI\>25 (2008)42.99±4.93Cigarette (2006)11.94±1.92Cigarette (2007)12.75±1.74Cigarette (2008)11.64±1.94Fruit (2006)1.13±0.24Fruit (2007)1.32±0.27Fruit (2008)1.42±0.40Vegetables (2006)1.25±0.38Vegetables (2007)1.38±0.42Vegetables (2008)1.41±0.44Low activity (2006)30.67±7.46Low activity (2007)34.88±8.38Low activity (2009)38.30±8.15Mahaki (2011)[@CIT0045]All of Iran---62,037MFSmoking0.97 (0.43--2.11)Socioeconomic0.92 (0.45--1.88)Islami (2007)[@CIT0046]TehranCase-control147 (case)\
39 (control)MFHPV virusei34.7\
7.6

The risk associated with cigarette smoking is considered to be an important disposal factor for the incidence of bladder cancer of 50%.[@CIT0003]

The use of opium in Iran over a hundred years is one of the most commonly used drugs. The number of addicts increases by 8% every year,[@CIT0018] also the largest growth is observed in northern and southern parts of Iran.[@CIT0019],[@CIT0020] As surveys show, opium consumption alone increases the chance of BC by 4.60-times ([Table 5](#T0005){ref-type="table"}).

#### Gender and Age {#S0003-S2006-S3001-S4001}

The results reveal the differences in the incidence and survival rate among men and women, as these are higher in the male population.[@CIT0003] In a meta-analysis study, the lowest incidence rate in Iranian women is estimated at 0.4 per 100,000 people.[@CIT0005] Factors such as differences in access to healthcare, late diagnosis, occupational exposure, pattern of Cigarette smoking, and the presence of steroid hormone in the two sexes[@CIT0003] are the reasons for these discrepancies. Increasing age as a risk factor plays an important role in the incidence of BC. The results of studies in Iran showed that the mean age of patients with BC in Iran was 65.1, 61.9, and 55.5 years,[@CIT0006] so that 47% of new cases in Iran are over 65 years old.[@CIT0021]

Lifestyle {#S0003-S2007}
---------

High consumption of alcohol,[@CIT0022],[@CIT0023] low consumption of vegetables and fruits, and low levels of drinking water,[@CIT0024] also, consumption of water containing halo methane chloride,[@CIT0016],[@CIT0025] Schistosoma infection (9--25%), and occupational exposure to aromatic amines,[@CIT0026] Chronic bladder infection, history of diabetes, and metabolic syndrome[@CIT0027] are associated with the risk of developing BC.

In this study, the association between alcohol consumption and malnutrition was reported to be around 9--57% ([Table 1](#T0001){ref-type="table"}), the majority of studies in the world also refer to the relationship between alcohol and BC.[@CIT0028] Family history, as an important factor, Increases the risk of malignancy by 22.32% ([Table 5](#T0005){ref-type="table"}), which itself indicates the role of genetics in the occurrence of this malignancy.[@CIT0029]

It should be noted that obesity increases the risk of BC by 1.04-fold ([Table 5](#T0005){ref-type="table"}). Since the relationship between obesity and type 2 diabetes is absolutely known, type 2 diabetes is associated with insulin resistance and serum IGF-1 levels, as in patients with BC, IGF-1 levels are significantly higher. On the other hand, diabetes is associated with an increased risk of bladder infection, which causes the higher incidence of BC.[@CIT0030] In the present study, diabetes also increased the risk of BC by 2.15-times ([Table 5](#T0005){ref-type="table"}).

Studies have shown that there is a relationship between diet and cancers.[@CIT0031] In this study, carbohydrates are associated with a 62% risk of BC incidence ([Table 5](#T0005){ref-type="table"}).

Meanwhile, taking green and yellow fruits and vegetables can have a protective effect on this disease. Fruits and vegetables reduce the risk due to the presence of alpha-beta-carotene, lycopene, lutein, and vitamins A, E, C, and F.[@CIT0032] In the investigated studies in Iran, the protective effect of fruits and vegetables was OR=0.97 (95% CI=0.94--1.00) and OR=0.93 (95% CI=0.99--0.99), respectively.

In contrast, a high intake of meat and fat is associated with the risk of this malignancy.[@CIT0032] As a result, the consumption of animal protein increases the risk of infection in Iran by about 5, and with animal fat the risk is elevated by \~19-times ([Table 5](#T0005){ref-type="table"}).

In a study, 34.7% of the patients with BC were found to have an HPV virus, while in the control group the infection was 7.6%, indicating a relationship between the HPV virus and the incidence of BC ([Table 5](#T0005){ref-type="table"}). In a meta-analysis, HPV outbreak worldwide was 16.88%,[@CIT0033] which is much lower than that reported in Iran. The difference can be due to genetic and environmental factors, sexual behavior, and ethnic and cultural differences in different parts of the world, including Iran.[@CIT0033]

Occupational Exposure {#S0003-S2008}
---------------------

In total, 20% of the causes of bladder cancer are due to occupational exposure.[@CIT0034] Based on previous research, the chance of developing BC among bus and heavy drivers is 11.3 (1.3--92.05), in farmers, fisheries, and forestry, it is 6.0 (2.32--15.72), and among metalworkers and welders it is 6.0 (2.84--14.08), these all being higher than others, such as carpenters, at 0.68 (0.35--1.25) ([Table 5](#T0005){ref-type="table"}).

On the other hand, evidence suggests that construction workers and those who deal with chemical substances are more likely to develop an invasive type of malignancy.[@CIT0035] The carcinogenic effects of occupational exposure are more due to the presence of benzidine, ortho-toluidine, 2- naphylamine, 4-aminobiphenyl, and 4,4ʹ-methylene-bis (2-chloroaniline) (MBOCA).[@CIT0016]

Conclusion {#S0004}
==========

The aim of this study was to determine the epidemiological aspects of bladder cancer in Iran. BC is the sixth most common cancer in the Iranian population, with a standardized incidence of 10.92 years for men and 2.80 for women. The incidence rate ranged from 1.6--115, the cumulative survival rate was 0.95, mortality ranged from 0.5--0.84, and the prevalence ranged from 4.10--12.8% . It seems that changes in Iranian lifestyle, as well as regular screening, can be effective in reducing the incidence and severity of this malignancy. Smoking and opium, consumption of red meat more than 4 times a week, animal fat, and occupational exposure such as bus and motor carriers are also considered risk factors for this cancer.
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